Invaron Pharmaceuticals Announces The First Canadian Pregnancy with INVOcell(TM)

KELOWNA, BC, July 25, 2013 /CNW/ - Today Invaron Pharmaceuticals announced that its ongoing Phase IV study of INVOcell has resulted in the first clinical pregnancy in Canada.

INVOcell is an innovative medical device that enables conception and early embryo development to occur within a woman's own body rather than in a laboratory.  "The INVO procedure provides a needed alternative to intrauterine inseminations and augments existing in vitro fertilization (IVF) services," commented Jason Broome, President of Invaron Pharmaceuticals.  "Utilizing the vaginal cavity as an incubator has the potential to dramatically increase access to fertility care because the capital costs and ongoing operating expenses associated with a traditional IVF laboratory are not part of the INVO procedure.  This allows considerable savings and can dramatically lower the overall cost of IVF services while maintaining similar pregnancy rates".

The study is chaired by Dr. Robert Casper, Medical Director of Toronto Centre for Advanced Reproductive Technology (TCART) in Toronto, ON. "We are excited to have achieved the first clinical pregnancy in Canada using INVOcell" said Dr. Casper.  "We believe that the INVO procedure may allow infertility treatment for couples who otherwise might not be able to access IVF because of geographical or financial reasons.  INVOcell offers a new therapeutic option for patients and we are excited to continue to explore the potential benefits in our phase IV study."

Dr. John McNaught, Medical Director of Fertility Ontario, who led patient recruitment and cycle monitoring for the study, further commented, "We are excited that several of the patients we enrolled in the study have ongoing pregnancies. INVOcell is going to broaden the choices available to fertility patients and we look forward to being a part of that."

About Invaron Pharmaceuticals
Invaron is a Canadian company focusing exclusively on the acquisition of niche drugs and medical devices. By facilitating local registration, bridging clinical gaps, and launching innovative marketing strategies, Invaron will meet the needs of Canadian patients in a variety of therapeutic areas.

INVOcellTM is a registered trademark of INVO Bioscience Inc., used under license by Invaron Pharmaceuticals Inc.

SOURCE: Invaron Pharmaceuticals Inc.

For further information:

Media contact
Jason Broome
Invaron Pharmaceuticals Inc.
jason.broome@invaron.ca
Ph:  250-869-0651

TCART contact
Dr. Robert Casper
casper@lunenfeld.ca
Ph:  416-972-0110

Fertility Ontario contact
Dr. John McNaught
jmcnaught@fertilityontario.com
Ph:  519-439-5555

Profil de l'entreprise

Invaron Pharmaceuticals Inc.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.